Howard S. Jonas, Chairman
Howard S. Jonas, serves as Chairman of the Board of Directors of Lipomedix. He has served as Chairman of the Board of Directors of Rafael Holdings, Inc. since August 17, 2017 and as Executive Chairman since June 13, 2022 and served as Chief Executive Officer from March 8, 2018 through April 30, 2021. Mr. Jonas has been a director of Cornerstone Pharmaceuticals since April 2013 and was appointed Chairman of the Board of Cornerstone Pharmaceuticals in April 2016. Mr. Jonas founded IDT in August 1990, has served as Chairman of its Board of Directors since its inception and as its Chairman since September 2022. Mr. Jonas served as member of the Board of Directors of IDT from inception to December 2020, when he was appointed as an ex-officio (non-voting) member of the Board of Directors. In March 2021, Mr. Jonas was reappointed as a voting member of the Board of Directors. Mr. Jonas served as Chief Executive Officer of IDT from October 2009 through December 2013 and from December 1991 until July 2001. From January 2014 until November 2017, Mr. Jonas served as the Chief Executive Officer of Genie Energy Ltd., a former subsidiary of IDT that was spun off to stockholders in October 2011, and has served as Chairman of the Board of Directors of Genie Energy since the spin-off. From June 2016 to November 2016, Mr. Jonas served as the Chairman of the Board of Zedge, Inc., a former subsidiary of IDT that was spun off to stockholders in June 2016. Mr. Jonas has served as the Vice Chairman of Zedge, Inc. since November 2016. Mr. Jonas also serves as Chairman of the Board of IDW Media Holdings, Inc., a former subsidiary of IDT that was spun off to stockholders in September 2009, has been its Chairman since June 2022 and served as Chief Executive Officer from February 2019 through April 2020. Mr. Jonas is also the founder and has been President of Jonas Media Group (f/k/a Jonas Publishing) since its inception in 1979. Mr. Jonas received a B.A. in Economics from Harvard University.
Eliyahu Shalom CEO
Eliyahu Shalom has served as Chief Executive Officer of Lipomedix since January 2023. Mr. Shalom has been with the Company since June 2021 serving as Managing Director of Business Development. Mr. Shalom served as Senior Project Manager, Digital & Technology, of IDW Publishing from June 2020 to February 2021. Mr. Shalom also worked in the Israeli Startup Hub Tel Aviv for Zirra.CO, LTD., a fintech company, as an AI Analyst from November 2018 to February 2019. He then was promoted to Project Manager, Scrum Master until April 2020. Mr. Shalom’s prior roles provided him with extensive experience in project management and problem solving. He holds a Bachelors of Science in Business Management with a concentration in Marketing from Brooklyn College. Mr. Shalom is currently pursuing a MBA from Bar-Ilan University (anticipated date of completion - June 2023).
Alberto Gabizon, MD, PhD, Chief Scientific Advisor
Alberto Gabizon, founder of Lipomedix is Professor of Oncology (Shaare Zedek Medical Center, The Hebrew University of Jerusalem) and a renowned scientist and clinician in the field of nanomedicine and cancer therapy. As co-inventor and co-developer of Doxil®, a smart chemotherapy "drug carrier" with tumor-targeting properties and important safety advantages, Professor Gabizon is one of the few scientists intimately familiar with the successful development and the clinical implementation of liposomal drugs. His most recent invention currently in clinical studies is Promitil® (pegylated liposomal mitomycin-C prodrug). Dr. Gabizon received his M.D. from the University of Granada in Spain, and his Ph.D. from the Weizmann Institute of Science in Israel. His clinical and research contributions in the field of liposomes and targeting therapy of cancers have been recognized by various awards among them the 2010 Alec Bangham Lifetime Achievement Award at the Liposome Research Days Conference in Vancouver, Canada, and the 1997 Kaye Innovation Award.
Patricia Ohana, PhD, VP Clinical Affairs
Dr. Patricia Ohana brings to LipoMedix over 25 years of experience and successful record in translating a product from pre-clinical to clinical stage in the development of anti-cancer drugs.
Prior to joining LipoMedix, Dr. Ohana most recently served as the Vice President of Research and Development and earlier, the Vice President of Clinical Development of BioCancell a biotech company dedicated to the development of DNA based drugs for the treatment of cancer. There she directed the development of their therapeutic product into multinational clinical trials. She previously held a position as research scientist in the Department of Biological Chemistry at the Hebrew University where she had a key role in the development of BC-819 as a drug for the treatment of cancer.
Dr. Ohana holds a PhD and a post-doctoral degree in Biological Chemistry from the Institute of Life Sciences at the Hebrew University of Jerusalem. She brings expertise in the field of biochemistry, molecular biology, oncology, DNA scale–up production, clinical development. Co-inventor of several patents.